QCG
PRCT icon

Quadrant Capital Group’s Procept Biorobotics PRCT Stock Holding History

Quadrant Capital Group’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-56
Closed -$1.4K – 2227
2026
Q1 		$1.4K Sell
56
-342
-86% -$9.64K ﹤0.01% 2545
2025
Q4 		$12.5K Buy
398
+384
+2,743% +$12.7K ﹤0.01% 2146
2025
Q3 		$500 Buy
+14
New +$639 ﹤0.01% 2617
2025
Q2 		– Sell
-28
Closed -$1.63K – 2275
2025
Q1 		$1.63K Sell
28
-52
-65% -$3.55K ﹤0.01% 2543
2024
Q4 		$6.44K Buy
80
+28
+54% +$2.39K ﹤0.01% 2252
2024
Q3 		$4.17K Buy
52
+24
+86% +$1.71K ﹤0.01% 2359
2024
Q2 		$1.71K Hold
28
– – ﹤0.01% 2497
2024
Q1 		$1.38K Hold
28
– – ﹤0.01% 2553
2023
Q4 		$1.17K Sell
28
-284
-91% -$9.67K ﹤0.01% 2540
2023
Q3 		$10.2K Buy
312
+289
+1,257% +$9.85K ﹤0.01% 1978
2023
Q2 		$814 Buy
+23
New +$760 ﹤0.01% 2521

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Quadrant Capital Group's PRCT Position: Q2 2026 in Review

Quadrant Capital Group sold out of Procept Biorobotics (PRCT) in Q2 2026, closing a stake of 56 shares — an estimated $1.4K sold.

Quadrant Capital Group first reported a position in PRCT in Q2 2023 and held it in 11 quarters. The position peaked at $12.5K in Q4 2025. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Quadrant Capital Group reported no remaining Procept Biorobotics position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 56 Procept Biorobotics shares in Q2 2026, an estimated $1.4K.
  • Quadrant Capital Group first reported a position in Procept Biorobotics in Q2 2023 and held it in 11 quarters.
  • Quadrant Capital Group's Procept Biorobotics position peaked at $12.5K in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.